Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.88 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.85 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.85 |
| ▸ | PDE2A | O00408 | 1/20 | 0.85 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.85 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.85 |
| ▸ | PDE6D | O43924 | 1/20 | 0.85 |
| ▸ | PDE8A | O60658 | 1/20 | 0.85 |
| ▸ | PDE9A | O76083 | 1/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | PDE6A | P16499 | 1/20 | 0.85 |
| ▸ | PDE6G | P18545 | 1/20 | 0.85 |
| ▸ | PDE4A | P27815 | 1/20 | 0.85 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.85 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | PDE6B | P35913 | 1/20 | 0.85 |
| ▸ | PDE6C | P51160 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848678 | 0.94 | PDE5A (0.95) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL29358004 | 0.94 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL17342850 | 0.94 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL7915874 | 0.92 | PDE5A (0.88) | PDE5APDE3BPDE3APDE2AABCC4 | |
| SCHEMBL5010426 | 0.92 | PDE5A (0.90) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Sildenafil SCHEMBL1895 | 0.92 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Sildenafil SCHEMBL5683880 | 0.92 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Sildenafil SCHEMBL29361663 | 0.92 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Lodenafil SCHEMBL31202790 | 0.92 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 | |
| Lodenafil SCHEMBL1058 | 0.92 | PDE5A (1.00) | PDE5APDE3BPDE3APDE2AABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | claimed |
| CN-116456963-A | NO-PDE5 inhibitors for the treatment of dry age-related macular degeneration, geographic atrophy and glaucoma-related neurodegeneration | 尼科斯股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | claimed |
| EP-3833395-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | Nicox S.A. (FR) | 2021-06-16 | — | — | EP | claimed |
| WO-2020030489-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2020-02-13 | — | — | WO | claimed |
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | NICOX S.A. (FR) | 2024-05-14 | — | — | US | disclosed |
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | NICOX S.A. (FR) | 2023-12-28 | — | — | US | disclosed |
| CN-116456963-A | NO-PDE5 inhibitors for the treatment of dry age-related macular degeneration, geographic atrophy and glaucoma-related neurodegeneration | 尼科斯股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3833395-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | Nicox S.A. (FR) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020030489-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE3B 3/4885PDE3A 2/4885 |
| US-20230414621-A1 | NO-PDE5 INHIBITOR FOR USE IN TREATING DRY AGE-RELATED MACULAR DEGENERATION, GEOGRAPHIC ATROPHY AND GLAUCOMA-ASSOCIATED NEURODEGENERATION | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE3B 4/4885PDE3A 3/4885 |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE6A, PDE3A | PDE5A 1/4885PDE3B 6/4885PDE3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.